Serebruany V - Search Results

1

Less Myocardial Infarction and Stroke Hospitalizations During Middle East Respiratory Syndrome Coronavirus Epidemic in Korea.

Jin C, Kim MH, Lee KM, Park JS, Jung DS, Yun SC, Serebruany V. Jin C, et al. Among authors: serebruany v. Am J Cardiol. 2020 Oct 1;132:176-178. doi: 10.1016/j.amjcard.2020.06.065. Epub 2020 Jul 3. Am J Cardiol. 2020. PMID: 32747005 Free PMC article. No abstract available.

2

Soluble vascular cell adhesion molecule-1 and E-selectin in patients with acute myocardial infarction treated with thrombolytic agents.

Gurbel PA, Serebruany VL. Gurbel PA, et al. Among authors: serebruany vl. Am J Cardiol. 1998 Mar 15;81(6):772-5. doi: 10.1016/s0002-9149(97)01035-7. Am J Cardiol. 1998. PMID: 9527091 Clinical Trial.

3

Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q-wave acute myocardial infarction.

Bahr RD, Gurbel PA, Malinin AI, Wentz C, Christenson RH, Roe MT, Gibler WB, Kitt MM, Ohman EM, Serebruany VL. Bahr RD, et al. Am J Cardiol. 2002 Aug 1;90(3):310-2. doi: 10.1016/s0002-9149(02)02470-0. Am J Cardiol. 2002. PMID: 12127619 No abstract available.

4

Cangrelor infusion is associated with an increased risk for bleeding: meta-analysis of randomized trials.

Serebruany VL, Aradi D, Kim MH, Sibbing D. Serebruany VL, et al. Int J Cardiol. 2013 Nov 5;169(3):225-8. doi: 10.1016/j.ijcard.2013.08.133. Epub 2013 Sep 7. Int J Cardiol. 2013. PMID: 24071381

5

Among antithrombotic agents, prasugrel, but not ticagrelor, is associated with reduced 30 day mortality in patients with ST-elevated myocardial infarction.

Serebruany VL, Cherepanov V, Tomek A, Kim MH. Serebruany VL, et al. Int J Cardiol. 2015 Sep 15;195:104-10. doi: 10.1016/j.ijcard.2015.05.062. Epub 2015 May 12. Int J Cardiol. 2015. PMID: 26043353

6

The Dual Antiplatelet Therapy Trial after the FDA Update: Noncardiovascular Deaths, Cancer and Optimal Treatment Duration.

Serebruany VL, Cherepanov V, Golukhova EZ, Kim MH. Serebruany VL, et al. Cardiology. 2015;132(2):74-80. doi: 10.1159/000431356. Epub 2015 Jun 23. Cardiology. 2015. PMID: 26111880

7

Survival After Solid Cancers in Antithrombotic Trials.

Serebruany VL, Tomek A, Kim MH. Serebruany VL, et al. Am J Cardiol. 2015 Sep 15;116(6):969-72. doi: 10.1016/j.amjcard.2015.06.026. Epub 2015 Jun 25. Am J Cardiol. 2015. PMID: 26189037

8

Low platelet activity predicts 30 days mortality in patients undergoing heart surgery.

Kuliczkowski W, Sliwka J, Kaczmarski J, Zysko D, Zembala M, Steter D, Zembala M, Gierlotka M, Kim MH, Serebruany V. Kuliczkowski W, et al. Among authors: serebruany v. Blood Coagul Fibrinolysis. 2016 Mar;27(2):199-204. doi: 10.1097/MBC.0000000000000418. Blood Coagul Fibrinolysis. 2016. PMID: 26366827

9

Should the Dose of Antiplatelet Drugs Be Adjusted for Body Weight? The Example of Vorapaxar.

Serebruany VL, Fortmann SD, Kim MH. Serebruany VL, et al. Cardiology. 2016;133(2):69-72. doi: 10.1159/000440798. Epub 2015 Oct 22. Cardiology. 2016. PMID: 26488178 Clinical Trial.

10

Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?

Serebruany VL, Tomek A, Pokov AN, Kim MH. Serebruany VL, et al. Expert Rev Cardiovasc Ther. 2015 Dec;13(12):1333-44. doi: 10.1586/14779072.2015.1101343. Epub 2015 Oct 29. Expert Rev Cardiovasc Ther. 2015. PMID: 26513059 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

393 results

Search Page

Filters